Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors.

Authors

• Heather S L Jim
• Sarah L Eisel
• Aasha I Hoogland
• Sandra Shaw
• Jennifer C King
• Adam P Dicker

Publication/Presentation Date

12-31-2020

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but few studies have reported on patient-reported outcomes (PROs) outside the context of a clinical trial. The goal of the current study was to assess PROs in participants of a lung cancer registry who had been treated with an ICI. Patients participating in the GO

Volume

13

Issue

1

ISSN

2072-6694

Published In/Presented At

Jim, H. S. L., Eisel, S. L., Hoogland, A. I., Shaw, S., King, J. C., & Dicker, A. P. (2020). Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors. Cancers, 13(1), 103. https://doi.org/10.3390/cancers13010103

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

33396286

Department(s)

Administration and Leadership

Document Type

Article